CJC-1295 with DAC vs Pancragen
Well Studied vs Moderate Research
monitor Mechanism-based · 47% Both CJC-1295 with DAC and Pancragen affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
CJC-1295 with DAC Pancragen
Weight 3,647.28 Da 576 Da
Half-life 6-8 days Not established
Chain 30 amino acids 4 amino acids
Type GHRH analog with DAC Tetrapeptide bioregulator
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Pancragen
01 Corrects impaired glucose tolerance
02 Normalizes insulin levels
03 Normalizes C-peptide levels
04 Improves endocrine pancreatic function
05 Supports pancreatic cell differentiation
06 Regulates melatonin expression
07 Reduces metabolic syndrome incidence
08 Upregulates key pancreatic transcription factors
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Pancragen
10-20mg daily / Daily for 10-20 days per cycle
Research protocol 0.05 mg/kg Daily for 10 days
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Pancragen
Generally well-tolerated
Minimal side effects reported
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Active pancreatic emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Type 1 diabetes (consult physician)
Research Evidence
CJC-1295 with DAC Pancragen
Status Well Studied Moderate Research
References 4 studies 4 studies
Latest 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.